News

FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-Positive Solid Tumors

04/08/2024

Stephanie Holland

The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.

The FDA granted accelerated...

04/08/2024

Oncology

Thierry André, MD, Saint Antoine Hospital

Videos

Nivolumab Plus Ipilimumab Yields Superior PFS vs Chemotherapy for First-Line Treatment of Metastatic Colorectal Cancer

01/23/2024

Thierry André , MD;

Thierry Andre, MD, discusses the first results from the CheckMate 8HW study exploring nivolumab plus chemotherapy for the first-line treatment of microsatellite instability-high, mismatch repair-deficient metastatic colorectal cancer.

Thierry Andre, MD, discusses the...

01/23/2024

Oncology

Jeanne Tie, MBChB, MD, Peter MacCallum Cancer Centre

Videos

Circulating Tumor DNA-Guided vs Standard Management of Locally Advanced Rectal Cancer

01/20/2024

Jeanne Tie , MBChB, MD;

Professor Jeanne Tie, MBChB, FRACP, MD, discusses results from the AGITG DYNAMIC-Rectal study, which explored a ctDNA-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.

Professor Jeanne Tie, MBChB,...

01/20/2024

Oncology

Conference Coverage

Significance of ctDNA Clearance Following Adjuvant Chemotherapy Among Patients with Radically Resected Colorectal Cancer

01/20/2024

Allison Casey ;

According to updated results from a substudy of the observational GALAXY study, detection of MRD via ctDNA and ctDNA dynamics in response to adjuvant chemotherapy for colorectal cancer were found to be highly prognostic of patient outcomes in...

According to updated results...

01/20/2024

Oncology

Conference Coverage

Combining Clinical Biomarkers for Optimal Selection of First-Line Treatment in Metastatic Colorectal Cancer

01/20/2024

Allison Casey ;

According to results from the phase 3 FIRE-3 study, the combination of primary tumor sidedness and liver-limited disease status may provide for the optimal selection of first-line treatment among patients with metastatic colorectal cancer.

According to results from the...

01/20/2024

Oncology

Conference Coverage

Role of ctDNA to Guide Adjuvant Chemotherapy Use for Patients With Colon Cancer

01/20/2024

Allison Casey ;

In the phase 2/3 COBRA study no improvement in ctDNA clearance was observed after 6 months of chemotherapy among patients with ctDNA detected following resection of stage IIA colon cancer.

In the phase 2/3 COBRA study no...

01/20/2024

Oncology

Videos

Using Liquid Biopsy to Guide Post-Surgical Treatment Among Patients With Colon Cancer

11/16/2023

Sara Lonardi ;

Sara Lonardi, MD, shares results from the PEGASUS trial which found post-surgical liquid biopsy may be used to guide the clinical management of patients with high-risk stage II or stage III colon cancer.

Sara Lonardi, MD, shares results...

11/16/2023

Oncology

News

FDA Grants Approval to Fruquintinib for Patients With Refractory Metastatic Colorectal Cancer

11/10/2023

Allison Casey ;

On November 8, 2023, the FDA approved fruquintinib for the treatment of patients with metastatic colorectal cancer who had previously been treated with multiple chemotherapies, an anti-VEGF therapy, and, if necessary, an anti-EGFR therapy.

On November 8, 2023, the FDA...

11/10/2023

Oncology

Filippo Pietrantonio, MD, National Cancer Center Milan

Videos

Sotorasib Plus Panitumumab Improved PFS Among Patients With Chemorefractory KRAS G12C-Mutated Metastatic Colorectal Cancer

11/07/2023

Filippo Pietrantonio ;

Primary results from the phase 3 CodeBreaK 300 trial found that sotorasib plus panitumumab improved progression-free survival among patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer, compared with the standard of...

Primary results from the phase 3...

11/07/2023

Oncology

Shinichi Nishina, MD, Kurashiki Central Hospital

Videos

RAS Status in ctDNA After Chemotherapy Among Patients With RAS-Mutant Colorectal Cancer

08/28/2023

Shinichi Nishina , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Shinichi Nishina, MD, reported data on that RAS status in ctDNA of patients with RAS-mutant metastatic colorectal cancer who responded to first- or second-line chemotherapy.

At the 2023 World Congress on...

08/28/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology